Cargando…
Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases
Sodium-glucose cotransporter 2 (SGLT2) inhibitor have become widely used in patients with diabetes, heart failure, and kidney disease to improve clinical outcomes and diminish hospitalizations. They have also been associated with increased serum magnesium levels in patients with type 2 diabetes. The...
Autores principales: | Shah, Chintan V., Robbins, T. Scott, Sparks, Matthew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519375/ https://www.ncbi.nlm.nih.gov/pubmed/36185705 http://dx.doi.org/10.1016/j.xkme.2022.100533 |
Ejemplares similares
-
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
por: Saha, Arunava, et al.
Publicado: (2022) -
Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport Inhibitor (SGLT-2i), a Case Report
por: Gandhi, Anand, et al.
Publicado: (2021) -
Home Subcutaneous Magnesium Infusion in Refractory Hypomagnesemia: A Case Report
por: Tokarski, Rebecca M., et al.
Publicado: (2023) -
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017) -
Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)